Omega-3 fatty acids, polymorphisms and lipid related cardiovascular disease risk factors in the Inuit population by Iwona Rudkowska et al.
Rudkowska et al. Nutrition & Metabolism 2013, 10:26
http://www.nutritionandmetabolism.com/content/10/1/26RESEARCH Open AccessOmega-3 fatty acids, polymorphisms and lipid
related cardiovascular disease risk factors in the
Inuit population
Iwona Rudkowska1,2, Catherine Ouellette1, Eric Dewailly3, Robert A Hegele4, Véronique Boiteau3,
Ariane Dubé-Linteau3, Belkacem Abdous3, Françoise Proust3, Yves Giguère3, Pierre Julien2,
Marie-Ludivine Château-Degat3 and Marie-Claude Vohl1,2*Abstract
Background: Tissue concentrations of fatty acids (FAs) and genetic variations are well-known factors which affect
the cardiovascular disease (CVD) risk. The objective was to examine whether the genetic variability of 20 candidate
genes and red blood cells (RBCs) percentage of total n-3 polyunsaturated fatty acids (PUFA), a biomarker of dietary
n-3 PUFA intake, modulate lipid related CVD risk factors in the Inuit population.
Methods: Data from the Qanuippitaa Nunavik Health Survey (n = 553) were analysed via multivariate regression
models with 40 known polymorphisms, RBCs percentage of n-3 PUFA, and the interaction term to take into
account the effect on plasma lipid and apolipoporotein levels.
Results: Individuals being heterozygotes for CETP C-4502T (rs183130) or G-971A (rs4783961) together with higher
n-3 PUFA had lower triacylglycerol (TG) concentrations compared to homozygotes for the minor allele. Further,
effects of a stronger beneficial association between n-3 PUFA in RBCs and plasma lipid parameters- including lower
total cholesterol (TC), lower low-density lipoprotein cholesterol (LDL-C) or higher high-density lipoprotein
cholesterol (HDL-C) concentrations- were associated with AGT M235T (rs699) TT genotype, CETP G-971A (rs4783961)
AG genotype, T allele carriers of CETP C-4502T (rs183130), and T allele carriers of CETP Ile405Val (rs5882). In contrast,
higher n-3 PUFA in RBCs were associated with adverse lipid profiles- including increased LDL-C, increased
apolipoprotein B100 or decreased HDL-C concentrations- in G allele carriers of the APOA5 -3 A/G (rs651821), C allele
carriers of APOA5 T-1131C (rs662799), G carriers of APOC3 SstI (rs5128) and G carriers of APOA4 Asn147Ser (rs5104).
Conclusion: Overall, these results suggest that percentage of total n-3 PUFA of RBCs are associated with lipids
related CVD risk factors conferred by genetic variations in the Inuit population.
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The lifestyle of the Inuit is rapidly changing towards an
increased cardiovascular (CVD) risk factor profile [1].
The CVD risk factors include non-modifiable risk fac-
tors such as age, male sex, family history, and modifiable
risk factors for example smoking, hypertension, diabetes,
and hyperlipidemia. Specifically, improving plasma lipids* Correspondence: marie-claude.vohl@fsaa.ulaval.ca
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distribution, and reproduction in any mediumprofile– including: total cholesterol (TC), triacylglycerol
(TG), low-density-lipoprotein cholesterol (LDL-C), apo-
lipoprotein (apo) B concentrations, apo A1 concentra-
tions and high-density-lipoprotein cholesterol (HDL-C)-
is associated with a decreased CVD risk [2]. Studies have
shown that both environmental and genetic factors may
play a role in determining susceptibility to dyslipidemia.
The consumption of fish and marine mammals rich in
n-3 PUFAs represents an important dietary component
for CVD risk prevention in the Inuit population [3]. A
high intake of n-3 polyunsaturated fatty acids (n-3
PUFAs), including eicosapentaenoic acid (EPA) (20:5(n-3))tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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shown to exert favorable effects on plasma lipid profiles
[4]. Recently, a study confirmed that higher percentages of
n-3 PUFA content in red blood cells (RBCs) were indica-
tive of higher n-3 PUFA intake in the Inuit population [5].
Nonetheless, an increased risk of lipid related CVD is cur-
rently occurring despite the substantial proportion of the
population maintaining traditional lifestyles including high
intakes of n-3 PUFAs [6].
The Inuit populations also carry a unique distinct gen-
etic background [7]. This genetic makeup has been
shown in some studies to be protective; yet, others have
reported potentially detrimental effects for CVD suscep-
tibility [1,8]. These genetic variations may render an in-
dividual more or less responsive to changes in n-3 PUFA
intake. Thus, gene-nutrient interactions may provide im-
portant insights into the inter-individual variability ob-
served in plasma lipid levels and thus on the risk of
CVD. Consequently, the main objective of this study
was to examine whether the genetic variability of 20
candidate genes in lipid metabolism and percentage of
total n-3 PUFA in RBCs - a biomarker of dietary n-3
PUFA intake, are associated with CVD risk factors in-




The data were collected in the framework of the Nunavik
Inuit Health Survey “Qanuippitaa? How are we?” conducted
among the Inuit of Nunavik in 2004. The survey covered all
14 Nunavik communities [6]. In the winter of 2009, partici-
pants from the Qanuippitaa Nunavik Health Survey in 2004
were revisited for the additional genetic component. Partici-
pants signed a consent form before data collection. Sam-
pling strategies for the present population-based study have
been described previously in detail [9]. All consent and
assent forms were approved by the Ethics Committee on
Research of Laval University and the Québec Public Health
Ethics review board.
Anthropometric measurements
Height was measured using a rigid square and a measur-
ing tape in a standardized standing position, with the
participant's back against the wall looking straight ahead,
and arms hanging down freely. Body weight was measured
with a scale (Tanita TBF-300, Manufacturer, Arlington
Heights, IL). Body mass index (BMI) was calculated as
weight per meter squared (kg/m2), and internationally
recommended cutoffs were used [10].
Plasma blood sampling
Blood samples were collected from an antecubital vein
into vacutainer tubes containing EDTA. Plasma wasseparated by centrifugation (2500 x g for 10 min at 4°C)
and samples were portioned and frozen for subsequent
measurements. Plasma TC and TG concentrations were
determined by enzymatic methods using a Hitachi 917
autoanalyser and reagents from Roche Diagnostics
(Canada) [11]. The HDL-C fraction was obtained dir-
ectly by precipitation with dextran sulfate-Mg2+ proced-
ure [11]. The LDL-C was calculated with the Friedewald
formula [12]. ApoB concentrations were measured in
plasma by the rocket immunoelectrophoretic method of
Laurell [13]. Lipid analyses were performed at the Centre
de Recherche sur les Maladies Lipidiques (Centre de
Recherche du CHUQ, Quebec, Qc, Canada).
Food frequency questionnaire (FFQ)
A food-frequency questionnaire (FFQ) [14] was adminis-
tered to the participants. A specifically designed 69-item
FFQ was used to assess average food and beverage in-
takes during the previous year, as described in more de-
tails elsewhere [15]. Analysis of the FFQ data provided
estimates of consumption frequency and the usual intake
in grams of country foods on a daily, weekly, monthly,
seasonal or an annual basis. Daily food intakes were cal-
culated on an annual basis by multiplying food con-
sumption frequency by intake in grams for each food.
Fatty acid determination
Fatty acid (FA) composition of erythrocyte membranes
was determined by gas chromatographic analysis. Mem-
branes of lysed erythrocytes were isolated by centrifuga-
tion (21,000g, 15 minutes) and washed twice with 0.9%
NaCl solution. Cell membranes were resuspended in 200
μL of the NaCl solution and were spiked with phosphat-
idylcholine C:15 (Avanti Polar Lipids, Alabaster, AL),
used as internal standard. Lipids were extracted using a
mixture of chloroform-methanol (2:1 v/v) according to a
modified Folch method [16]. FA profiles were obtained
after methylation in methanol/benzene 4:1 (v/v) [17] and
capillary gas chromatography using a temperature gradi-
ent on a HP5890 gas chromatograph (Hewlett Packard,
Toronto, Canada) equipped with a HP-88 capillary col-
umn (100m x 0.25 mm i.d. x 0.20μm film thickness;
Agilent Technologies, Palo Atto, CA) coupled with a
flame ionization detector (FID). Helium was used as car-
rier gas (split ratio 1:80). FA were identified according to
their retention time, using the following standard mix-
tures as a basis for comparison: the FAME 37 mix
(Supelco Inc., Bellefonte, PA) and the GLC-411 fatty acid
mix (NuChek Prep Inc, Elysian, MN), as well as the fol-
lowing methylated fatty acids C22:5 n-6 (Larodan AB,
Malmö, Sweden) and C22:5 n-3 (Supelco Inc., Bellefonte,
PA). Erythrocyte FA profiles were expressed as the rela-
tive percentage areas of total FAs. Total percentage of n-
3 PUFAs in RBCs was calculated from the sum of C18:3
Table 1 Genes, polymorphisms and the main function their protein
Genes (Official symbol) Polymorphisms Main function of their protein
Angiotensin I converting enzyme (ACE) I/D alleles (rs4343) Involved in regulating blood pressure




Apolipoprotein A-I (APOA1) G-75A (rs670) Component of HDL particles
84 T/C (rs5070)
Apolipoprotein A-IV (APOA4) Asn147Ser (rs5104) Activates lecithin-cholesterol acyltransferase (LCAT)




Apolipoprotein B (APOB) XbaI (rs693) Component of LDL particles
Apolipoprotein C-III (APOC3) SstI (rs5128) Major component of TG-rich lipoproteins
T-455C (rs2854116)




ATP-binding cassette, sub-family A (ABC1),
member 1 (ABCA1)
Arg219Lys (rs2230806) Transports cholesterol and phospholipids through the cell
membrane to outside the cell
Cholesteryl ester transfer protein, plasmatique
(CEPT)





Cytochrome P450, family 1, subfamily A,
polypeptide 1 (CYP1A1)
Msp1 (rs4646903) Catalyses reactions involved in drug metabolism and
synthesis of cholesterol, steroids and other lipids
A4889G (rs1048943)
Fat mass and obesity associated (FTO) rs9939609 Linked to obesity and diabetes
Glucokinase (hexokinase 4) regulator (GCKR) rs780094 Inhibitor and glucokinase
Insulin induced gene 2 (INSIG2) rs7566605 Connected to the metabolism of lipids, cholesterol, and
obesity
Lipoprotein lipase (LPL) HindIII (rs320) Hydrolyses TG-rich lipoproteins
Ser447Ter (rs328)




C677T (rs1801133) Catalyzes the conversion of a co-substrate for
homocysteine
Paraoxonase 1 (PON1) L55M (rs854560) Reduces LDL-oxidation
Gln192Arg (rs662)
C-107T (rs705379)
Peroxisome proliferator-activated receptor gamma
2 (PPARG2)
Pro12Ala (rs1801282) Regulator of adipocyte differentiation
−681 C/G (rs10865710)
Transcription factor 7-like 2 (TCF7L2) C47833T (rs7903146) Transcription factor
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(n-3), C22:5 (n-3) (docosapentaenoic acid (DPA)), and
C22:6 (n-3) (DHA).DNA extraction and genotyping
DNA was extracted from 100 μl of buffy coat using the
QIAamp 96 DNA Blood Kit (QIAGEN Inc., Valencia,
CA, USA). Quant-iT PicoGreenW dsDNA Assay Kit
(Invitrogen) was used to quantify DNA. DNA was
analysed with TaqManW Pre-Designed SNP Genotyping
Assays according to the manufacturer's instructions at
the McGill University/Génome Québec Innovation Cen-
ter (Montreal, Canada).
From a literature review, 40 polymorphisms in 20 genes
relating to lipid metabolism were identified (Table 1)
namely: Angiotensin I converting enzyme (ACE) I/D alleles
(rs4343), Angiotensinogen (AGT) M235T (rs699), T174M
(rs4762), A-20C (rs5050), A-6G (rs5051); Apolipoprotein
A-I (APOA1) G-75A (rs670), 84 T/C (rs5070); Apolipopro-
tein A-IV (APOA4) Asn147Ser (rs5104); Apolipoprotein A-
V (APOA5) T-1131C (rs662799), -3 A/G (rs651821), S19W
(rs3135506), Gly185Cys (rs2075291); Apolipoprotein B
(APOB) XbaI (rs693); Apolipoprotein C-III (APOC3) SstI
(rs5128), T-455C (rs2854116); Apolipoprotein E (APOE)
Cys112Arg (rs429358), Arg158Cys (rs7412), G-219T
(rs405509); ATP-binding cassette, sub-family A (ABC1),
member 1 (ABC1A) Arg219Lys (rs2230806); Cholesteryl
ester transfer protein (CETP) TaqIB (rs708272), C-629A
(rs1800775), C-4502T (rs183130), G-971A (rs4783961),
Ile405Val (rs5882); Cytochrome P450, family 1, subfamily
A, polypeptide 1 (CYP1A1) Msp1 (rs4646903), A4889G
(rs1048943); Fat mass and obesity associated (FTO)
(rs9939609); Glucokinase (hexokinase 4) regulator (GCKR)
(rs780094); Insulin induced gene 2 (INSIG2) (rs7566605);
Lipoprotein lipase (LPL) HindIII (rs320), Ser447Ter
(rs328); Hepatic lipase (HL or LIPC) C-514T (rs1800588),
G-250A (rs2070895); Methylenetetrahydrofolate reductase
(NAD(P)H) (MTHFR) C677T (rs1801133); Paraoxonase 1
(PON1) L55M (rs854560), Gln192Arg (rs662), C-107T
(rs705379); Peroxisome proliferator-activated receptor
gamma 2 (PPARG2) Pro12Ala (rs1801282), 681 C/G
(rs10865710); Transcription factor 7-like 2 (TCF7L2)
C47833T (rs7903146).Statistical analysis
Hardy-Weinberg equilibrium (HWE) was tested with the
Allele Procedure in SAS, version 9.2 (SAS Institute Inc,
Cary, NC). Distribution of alleles between the Inuit and
Caucasian populations has previously been reported [7].
After completion of the recruitment, a group of 501 par-
ticipants was calculated to provide an 80% probability
and 5% significance level of detecting an anticipated dif-
ference of 0.10 mmol/L for TG concentrations (primaryoutcome) with a genetic variation that occurs in a rela-
tively low frequency (>10%) of the population.
Data are shown as mean ± standard error of mean (S.
E.M). Further, variables were checked for normality.
Plasma TG and ratio TC/ HDL-C were transformed by
natural logarithm to normalize their distribution. A stat-
istical model was used to evaluate the effect of the poly-
morphism, RBC percentage of total n-3 PUFA as a
continuous variable, and the polymorphism by RBCs
percentage of total n-3 PUFA interaction effect, adjusted
for the effects of age, sex, BMI, and total energy intake
(kcal) on each of the lipid variables. Then, the absolute
values of the regression beta- (β) coefficient were derived
to estimate the phenotypic difference contributed by
each of the genotype by RBC percentage of total n-3
PUFA interaction effect. In addition, to test for the addi-
tive effects of multiple polymorphisms, a “risk score”
was calculated based on the number of risk genotypes
an individual carried from all the significant polymorph-
ism by RBCs percentage of total n-3 PUFA interactions
for each lipid parameter. A statistical model was used to
evaluate the effect of the “risk score”, RBCs percentage
of total n-3 PUFA as a continuous variable, and the risk
score by RBCs percentage of total n-3 PUFA interaction
effect, adjusted for the effects of age, sex, BMI and en-
ergy intake (kcal) on each of the lipid variables. Again,
the absolute value of the regression β- coefficient was
calculated to estimate the phenotypic difference contrib-
uted by the number of risk genotypes and percentage of
total n-3 PUFA in RBCs interaction effects. When sig-
nificant differences were found, a comparison pairwise
was performed in a global analysis (Tukey tests; signifi-
cance P ≤ 0.05). Statistical analyses were performed with




In summary, 677 households were contacted of which
521 agreed to participate including 1056 individuals who
signed a consent form and 917 who agreed to the collec-
tion of blood samples. In addition, 769 participants com-
pleted the FFQ. For the additional genetic component,
658 individuals from the original individuals gave con-
sent. Consequently, the statistical analyses were done for
all individuals where plasma lipid concentrations, per-
centage of total n-3 PUFA in RBCs, energy intake and
genotypes were available. Therefore, 553 participants
were included. The baseline characteristics, plasma lipids
levels, percentage of total n-3 PUFAs in RBCs, and daily
energy intake are described in Table 2. Briefly, higher
RBC percentages of n-3 PUFA in the Inuit population
were associated to lower TG concentrations (P = 0.0119),
higher TC (P = 0.0001) including higher HDL-C (P <
Table 2 Baseline characteristics of the study subjects
Men (n = 251) Women (n = 302)
Anthropometrics
Age 37.1 ± 0.9 37.3 ± 0.8
Weight (kg) 74.5 ± 1.0 65.9 ± 0.9
Height (cm) 165.8 ± 0.4 154.0 ± 0.3
BMI (Kg/m2) 27 ± 0.3 28 ± 0.4
Hypercholesterolemia (n,% of total) 22 (9%) 21 (7%)
Plasma Lipids
Total Cholesterol (mmol/L) 4.94 ± 0.06 5.04 ± 0.05
HDL- Cholesterol (mmol/L) 1.48 ± 0.02 1.79 ± 0.03
LDL- Cholesterol (mmol/L) 2.89 ± 0.06 2.74 ± 0.05
Total/HDL- Cholesterol ratio 3.52 ± 0.07 2.96 ± 0.05
Triglycerides (mmol/L) 1.25 ± 0.04 1.11 ± 0.04
ApoB100 (mmol/L) 0.97 ± 0.02 0.93 ± 0.01
ApoA1 (mmol/L) 1.62 ± 0.02 1.77 ± 0.02
n-3 PUFA in RBCs
Eicosapentaenoic acid (EPA) (%) 1.52 ± 0.08 1.82 ± 0.07
Docosapentaenoic acid (DPA) (%) 2.17 ± 0.03 2.21 ± 0.03
Docosahexaenoic acid (DHA) (%) 5.11 ± 0.12 5.80 ± 0.11
Total n-3 PUFAs (%) 9.14 ± 0.22 10.19 ± 0.20
Daily Intake
Total Energy Intake (KJ) 10932 ± 352 9291 ± 301
Total percentage of n-3 PUFAs in RBCs was calculated from the sum of C18:3
(n-3), C18:4 (n-3), C20:4 (n-3), C20:5 (n-3) (EPA), C22:3 (n-3), C22:5 (n-3) (DPA),
and C22:6 (n-3) (DHA).
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without changing the TC/HDL ratio and plasma apoB100
levels when adjusted for age, sex, BMI and energy intake.
Genotypic characteristics
Genotype frequencies did not deviate from those predicted
by the Hardy-Weinberg equilibrium except for the follow-
ing 3 SNPs: LPL HindIII (rs320), LPL Ser447Ter (rs328)
and TCF7L2 C47833T (rs7903146) which were excluded
from statistical analyses. The minor alleles of the following
SNPs: AGT T174M (rs4762), AGTA-20C (rs5050), APOA5
Gly185Cys (rs2075291), APOA5 S19W (rs3135506), APOE
Cys112Arg (rs429358), and FTO (rs9939609) had low fre-
quencies (MAF < 0.10) in the Inuit population and were
also excluded from analyses. In addition, allele frequencies
were significantly different (P ≤ 0.05) in 18 SNPs in the
Inuit population comparatively to the Caucasian popula-
tion, as previously described [7].
Gene- diet interactions for CVD risk factors
Statistical analyses revealed 8 SNPs by percentage of n-3
PUFA in RBCs interactions for plasma lipid concentrations
(Table 3). Briefly, subjects heterozygous for CETP C4502T
(rs183130) or G-971A (rs4783961) had significantly lowerplasma TG concentrations with higher n-3 PUFA percent-
age in RBCs compared to homozygotes for the minor
allele. In addition, a more favorable plasma lipid profiles
when higher percentages of n-3 PUFA were observed:
lower plasma TC for T carriers of CETP C4502T
(rs183130) or lower plasma TC/HDL ratio for CETP G-
971A (rs4783961) for AG genotype. Participants homozy-
gous for the T allele of CETP Ile405Val (rs5882) had lower
plasma TC and T carriers of CETP Ile405Val (rs5882) had
higher plasma HDL-C concentrations when higher per-
centage of n-3 PUFA in RBCs were observed. Secondly, for
APOA5, G carriers of −3 A/G (rs651821) or C carriers of
T-1131C (rs662799) exhibited higher plasma LDL-C con-
centrations, lower plasma HDL-C concentrations, a higher
plasma TC/HDL ratio as well as higher apoB100 levels
when they had a higher percentage of total n-3 PUFA in
RBCs. Thirdly, carriers of the mutated allele of AGT
M235T (rs699), compared to wild-type genotype, had de-
creased plasma TC and LDL-C concentrations when
higher n-3 PUFA percentage were observed. Forth, G allele
carriers of APOA4 Asn147Ser (rs5104) had greater
apoB100 concentrations with higher percentage of n-3
PUFA. Finally, subjects carrying the G allele of APOC3 SstI
(rs5128) had increased TC/ HDL ratio and apoB100 con-
centrations with higher percentage of n-3 PUFA. Addition-
ally, a higher number of these above “risk alleles” in
interaction with percentage of total n-3 PUFA were associ-
ated with significantly higher TG (P = 0.0069), TC (P =
0.0010), LDL-C (P = 0.0025) and apoB100 (P = 0.0044) con-
centrations as well as TC/HDL-C ratio (P = 0.0004) to-
gether with lower HDL-C (P = 0.0030) concentrations.
Overall, polymorphisms in CETP, AGT, APOA5, APOA4
and APOC3 and the percentage of n-3 PUFA in RBCs are
associated with plasma lipid concentrations in the Inuit
population.
Discussion
Results suggest that genetic factors and the percentages
of n-3 PUFA in RBCs influence CVD risk factors in the
Inuit population. Specifically, results demonstrate that 8
SNPs in 5 candidate genes: CETP ((rs5882) (rs183130)
and (rs4783961)), AGT (rs699), APOA5 ((rs651821) and
(rs662799)), APOA4 Asn147Ser (rs5104), and APOC3
(rs5128), are associated with plasma lipid concentrations
in interaction with the percentages of n-3 PUFA in RBCs
in the Inuit population.
Higher percentage of n-3 PUFA in the Inuit popula-
tion were associated with lower TG levels, higher TC in-
cluding HDL-C and LDL-C concentrations without
affecting the TC/HDL ratio and plasma apoB100 levels.
In the same way, a meta-analysis that combined 21 trials
with consumption of fish oil, reported a decrease in
plasma TG concentrations and an increase in HDL-C
and LDL-C concentrations without changes in TC








β ± SEM P-Value for
Interaction effect
Total cholesterol (TC) AGT 0.1453 0.4455 C/C (71%) 0a 0.0448
M235T C/T (26%) 0.0210 ± 0.0262a
rs699* T/T (3%) −0.1482 ± 0.0651b
CETP 0.0152 <0.0001 C/C (36%) 0a 0.0326
C-4502T C/T (49%) −0.0632 ± 0.0241b
rs183130 T/T (15%) −0.0421 ± 0.0343ab
CETP 0.1115 0.0002 C/C (26%) 0ab 0.0334
Ile405Val C/T (47%) 0.0397 ± 0.0268a
rs5882* T/T (26%) −0.0290 ± 0.0307b
LDL-Cholesterol (LDL-C) AGT 0.1514 0.6339 C/C (71%) 0a 0.0405
M235T C/T (26%) 0.0299 ± 0.0238 a
rs699* T/T (3%) −0.1228 ± 0.0592b
APOA5 0.012 0.0018 A/A (42%) 0a 0.006
−3 A/G G/A (45%) 0.0678 ± 0.0213b
rs651821 G/G (13%) 0.0474 ± 0.0332ab
APOA5 0.0137 0.0035 T/T (42%) 0a 0.0072
T-1131C T/C (44%) 0.0669 ± 0.0213b
rs662799 C/C (34%) 0.0427 ± 0.0339ab
HDL-Cholesterol (HDL-C) APOA5 0.126 0.0002 A/A (42%) 0a 0.0065
−3 A/G G/A (45%) −0.0317 ± 0.0100b
rs651821 G/G (13%) −0.0105 ± 0.0155ab
APOA5 0.01476 0.0002 T/T (42%) 0a 0.0072
T-1131C T/C (44%) −0.0314 ± 0.0100b
rs662799 C/C (34%) −0.0115 ± 0.0159ab
CEPT 0.2302 0.0017 C/C (26%) 0a 0.0271
Ile405Val C/T (47%) 0.0263 ± 0.0115b
rs5882* T/T (26%) 0.0017 ± 0.0131a
Triglycerides (TG) CETP 0.0092 0.3779 C/C (36%) 0ab 0.0300
C-4502T T/C (49%) −0.0095 ± 0.0051a
rs183130 T/T (15%) 0.0073 ± 0.0073b
CETP 0.0087 0.399 G/G (28%) 0ab 0.0032
G-971A A/G (50%) −0.0106 ± 0.0057a
rs4783961 A/A (22%) 0.0087 ± 0.0068b
Ratio Total Cholesterol/
HDL-Cholesterol
APOC3 0.2263 0.7503 C/C (33%) 0a 0.0137
SstI C/G (46%) 0.0081 ± 0.0030 b
rs5128* G/G (21%) 0.0085 ± 0.0039 b
APOA5 0.0016 0.5195 A/A (42%) 0a <0.0001
−3 A/G G/A (45%) 0.0128 ± 0.0028 b
rs651821 G/G (13%) 0.0053 ± 0.0044ab
APOA5 0.0018 0.62 T/T (42%) 0a <0.0001
T-1131C T/C (44%) 0.0126 ± 0.0028b
rs662799 C/C (14%) 0.0050 ± 0.0045ab
CETP 0.188 0.8473 G/G (28%) 0ab 0.0483
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Table 3 Impact of the SNP, RBCs total n-3 PUFA and the interaction SNP * RBCs total n-3 PUFA on plasma lipids and
lipoproteins levels (Continued)
G-971A A/G (50%) −0.0055 ± 0.0033a
rs4783961 A/A (22%) 0.0022 ± 0.0039b
ApoB100 APOC3 0.0374 0.0399 C/C (33%) 0a 0.0073
SstI C/G (46%) 0.0179 ± 0.0058 b
rs5128* G/G (21%) 0.0145 ± 0.0076 ab
APOA4 0.0277 0.0221 A/A (33%) 0a 0.0052
Asn147Ser A/G (45%) 0.0178 ± 0.0058b
rs5104 G/G (22%) 0.0177 ± 0.0073b
APOA5 0.0006 0.091 A/A (42%) 0a 0.0002
−3 A/G G/A (45%) 0.0229 ± 0.0055b
rs651821 G/G (13%) 0.0086 ± 0.0086ab
APOA5 0.0009 0.0516 T/T (42%) 0a 0.0002
T-1131C T/C (44%) 0.0227 ± 0.0055b
rs662799 C/C (34%) 0.0117 ± 0.0088ab
β regression coefficient, P values are calculated with normalized values; β regression coefficient are derived from absolute values, a,b Means with different
subscript letters for one SNP are significantly different after adjustment for Tukey test; * Genotype frequency is different between the Inuit and Caucasian
populations; The model includes the SNP, n-3 PUFA in RBCs, and the interaction term with adjustment for the effects of age, sex, BMI, and daily energy intake.
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percentages of n-3 PUFA in RBCs on CVD risk factors
in the Inuit population are similar to those previously
reported; however, gene-nutrient interactions contribute
the inter-individual variability observed in the plasma
lipid levels in this population.
Heterozygotes for CETP C4502T (rs183130) or G-
971A (rs4783961) had lower plasma TG concentrations
with higher percentages of n-3 PUFA compared to the
homozygotes for the minor allele. In addition, these het-
erozygotes for CETP C4502T or G-971A had lower
plasma TC levels or TC/HDL ratio with higher percent-
ages of n-3 PUFA compared to homozygotes for the rare
allele, respectively. CETP plays a central role in HDL-C
metabolism by shuttling cholesteryl esters from HDL
particles to apoB- containing particles, partly in ex-
change for TG [19]. It is well-known that several genetic
variants in the CETP gene are associated with altered
plasma HDL-C concentrations, lipoprotein particle sizes,
CETP plasma concentrations and activity, and perhaps
the risk of coronary artery disease [19]. Earlier, Corella
et al., [20] demonstrated no gene-environment interac-
tions, including total fat, saturated fat and monounsatu-
rated fat- for the CETP C4502T SNP on HDL-C
concentrations. We have also demonstrated no interaction
with total fat or saturated fat intake with this SNP on
plasma lipid levels [7]; however, in the present study, the
inclusion of n-3 PUFA in the diets of wild-type or hetero-
zygotes for CETP would favor an improved cardiovascular
risk profile compare to carriers of the minor allele.
Further, carriers of the T allele for CETP Ile405Val
(rs5882) decreased plasma TC and increased plasmaHDL-C concentrations with higher percentages of n-3
PUFA. This functional SNP, corresponding to the substi-
tution of a valine for an isoleucine caused by a C→T
mutation, has been associated with lower CVD risk via
lowering of CETP protein concentration and activity;
consequently, increasing HDL-C levels and lipoprotein
particle sizes [21]. Previously, Darabi et al., [22] demon-
strated that subjects carrying the C allele of CETP
Ile405Val had greater reduction in plasma HDL-C and
apoAI concentrations than subjects carrying a T allele
when a high-PUFA: saturated diet was replaced with a
low- PUFA: saturated diet [22]. Together, these studies
suggest that PUFA intake in individuals with CETP
Ile405Val polymorphism contributes to the variability of
plasma lipids concentrations.
Similarly, higher percentage of n-3 PUFA in carriers of
the T allele of AGT M235T (rs699) were associated with
lower plasma TC and LDL-C concentrations than car-
riers of the wild-type allele. The M235T polymorphism
in the AGT gene has been associated to an increased
CVD risk in the presence of hypercholesterolemia [23].
In a previous study with this Inuit population, we dem-
onstrated that carriers of the minor allele of M235T
AGT with high total and saturated fat intake exhibited
higher plasma TC and LDL-C concentrations [7]. Taken
together, these results suggest that carriers of the AGT
M235T should consume a diet high in n-3 PUFA and
low in saturated fat, to reduce their risk of CVD.
In contrast, G allele carriers of APOA5 -3 A/G
(rs651821) or C allele carriers of APOA5 T-1131C
(rs662799) had a more deteriorated lipid profile includ-
ing higher plasma LDL-C and apoB100 concentrations,
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C concentrations with higher percentage of n-3 PUFA in
RBCs. APOA5 regulates TG metabolism; therefore, differ-
ent SNPs in APOA5 may be associated with TG concen-
trations and CVD risk factors [24]. Variations in this gene
have been previously associated with plasma lipid levels
via modulation of dietary intake. First, an interaction of
the APOA5 T-1131C polymorphism with energy intake
and total fat was observed for plasma TG and TC concen-
trations in a population of Puerto Rican older adults [25].
Secondly, a study in the Mediterranean population
reported a positive association between fat intake and
obesity in homozygotes for the T allele of APOA5 T-
1131C, whereas in subjects carrying the APOA5 T-1131C
polymorphism, higher fat intakes were not associated with
higher BMI and TG-rich lipoproteins [26]. Finally, Lai
et al., [27] suggest that high PUFA-rich diets, specifically
n-6 PUFAs, are related to a more atherogenic lipid profile
in individuals of the Framingham Heart Study with the
APOA5 T-1131C polymorphism. Overall, results suggest
that SNPs in APOA5 are determinants of variation in lipid
response to n-3 PUFA intake; however, the outcome of
these gene-nutrient interactions needs to be investigated
further.
Further, carriers of the G allele of APOA4 Asn147Ser
(rs5104) had higher apoB100 levels with higher percent-
ages of n-3 PUFA in RBCs. It has been suggested that
APOA4 plays an important role in the metabolism of
TG-rich lipoproteins [28]. APOA4 variants may alter
protein and thus have been linked to baseline TG con-
centrations [28] and TG in response to fenofibrate treat-
ment [29]. A study demonstrated that carriers of the
minor allele of APOA4 Asn147Ser had lower plasma
apoA1 concentrations in a postprandial state after a high
saturated meal [24]. Together, results demonstrate that
carriers of the minor allele of APOA4 Asn147Ser may be
more sensitive to changes in dietary fat.
Similarly, carriers of the APOC3 G minor allele of SstI
(rs5128) had increased TC/HDL ratio and plasma
apoB100 concentrations with higher percentages of n-3
PUFA. APOC3 increases plasma TG concentrations by
inhibiting the lipoprotein lipase activity and by altering
the Apo-E mediated uptake of TGs. The G- allele has
been associated with elevated plasma TC, TG, and apoC-
III concentrations [30]. Lopez-Miranda et al., [31] demon-
strated an increase in plasma LDL-C concentrations in
the CC subjects after consumption of a diet high in mono-
unsaturated fatty acids whereas a decrease was observed
in the CG subjects. Taken as a whole, results demonstrate
that carriers of the APOC3 G allele of SstI may benefit
more from a high monounsaturated diet compared to an
n-3 PUFA diet.
Since the effect size of each SNP was small even if the
interaction was statistically significant, we demonstratedan additive effect of these SNPs in interaction with per-
centage of n-3 PUFA for all CVD risk factors. Thus, this
demonstrates that it is possible to develop models with
advantageous and disadvantageous alleles together with
dietary intake data and predict the risk of a deteriorated
lipid profile in a specific population. However, the major
limitation for the study is the limited number of SNPs
chosen based on previous research findings. If such
models would be developed, large studies using numer-
ous genetic variations should be included to be able to
assess the greatest variability.
Conclusions
Overall, these results suggest that the percentages of n-3
PUFA in RBCs, as an indicator of n-3 PUFA intake and
genetic variations in CETP, AGT, APOA5, APOA4 and
APOC3, in the Inuit population are associated with CVD
risk factors. In general, n-3 PUFA consumption has fa-
vorable effects on lipid related CVD risk factors; how-
ever, some genetic subgroups may benefit to greater
extent from a higher intake of n-3 PUFA for lipid related
CVD risk factors.
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